



Translational Biomedical Research: Bridging Infectious Diseases, Cancer Biology, Phytomedicine, and Bioinformatics. An Integrated Review

Venkatajothi Ramarao

Department of Microbiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Thandalam, Chennai - 602105, Tamil Nadu, India.

***Correspondence author: Dr. Venkatajothi Ramarao**

Address for correspondence: Department of Microbiology, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Thandalam, Chennai - 602105, Tamil Nadu, India.

Email id: drvjothi10@gmail.com; venkatajothir.smc@saveetha.com

Abstract

Translational biomedical research represents a critical paradigm that bridges fundamental scientific discoveries with clinical applications, addressing the growing global burden of infectious diseases and cancer. This integrated review synthesizes advances across four interconnected domains: infectious disease epidemiology, cancer biology, phytomedicine, and bioinformatics. Infectious diseases, including parasitic, fungal, bacterial, and viral infections, continue to pose significant public health challenges, particularly in resource-limited settings. Concurrently, cancer remains a leading cause of mortality worldwide, necessitating novel therapeutic strategies beyond conventional approaches. Phytomedicine offers a promising reservoir of bioactive compounds with demonstrated antioxidant, anti-inflammatory, antibacterial, and anticancer properties, providing natural alternatives to synthetic pharmaceuticals. Plant species such as *Boerhaavia diffusa*, *Euphorbia hirta*, *Achyranthes aspera*, *Ipomoea obscura*, and *Terminalia chebula* have shown remarkable therapeutic potential across multiple disease targets. Furthermore, bioinformatics and computational approaches, including molecular docking, in silico peptide design, and network pharmacology, have revolutionized drug discovery by enabling rapid identification of novel therapeutic candidates. The integration of these disciplines facilitates the development of evidence-based, multi-target therapeutic interventions. This review highlights the translational potential of combining traditional ethnopharmacological

knowledge with modern computational methodologies, ultimately accelerating the pipeline from bench to bedside in addressing complex, multifactorial diseases.

Keywords: Translational Biomedical Research, Infectious Diseases, Cancer Biology, Phytochemistry, Bioinformatics.

1. Introduction

Science rarely moves in straight lines. Translational biomedical research, often described simply as "bench to bedside," is perhaps the clearest example of how messy, nonlinear, and ultimately rewarding that journey can be. For decades, researchers working on infectious diseases, cancer, medicinal plants, and computational biology operated in fairly separate worlds. That separation made sense once, but it no longer does [1, 2, 3]. Infectious diseases continue to claim millions of lives annually, and cancer remains one of the leading causes of death worldwide [4, 5]. At the same time, growing antimicrobial resistance and chemotherapy toxicity have pushed scientists to look elsewhere for solutions [6, 7].

Phytochemistry has re-entered serious scientific conversation, and bioinformatics now offers tools that can analyze complexity at a scale previously unimaginable [8, 9]. What makes this moment genuinely exciting is the convergence. Researchers are using computational platforms to screen plant metabolites against cancer targets, while simultaneously studying how pathogens exploit similar molecular pathways [10, 11]. The boundaries are blurring in productive ways. This review reflects on that convergence, drawing from recent literature and original investigations across all four domains [12, 13].

2. Infectious Disease Research: Old Threats, New Approaches

Infectious diseases have shaped human history more profoundly than almost anything else. From the plague to HIV to COVID-19, pathogens have repeatedly forced medicine to adapt, innovate, and sometimes completely rethink its assumptions [14, 15]. What is different now is the speed and sophistication of our response.

Modern infectious disease research has moved well beyond simply identifying causative organisms. Scientists are now deeply interested in host-pathogen interactions, immune evasion strategies, and the molecular signatures that determine why some people get severely ill while others do not [16, 17]. Early clinical observations, such as documenting the incidence of intestinal protozoan infections among school-going children, laid important groundwork for understanding community-level disease burden [18]. Similarly, prevalence studies of intestinal helminthic infections helped establish baseline epidemiological data that still informs public health planning today [19].

Fungal infections, often overlooked in the shadow of bacterial and viral diseases, carry their own clinical significance. Studies of tinea capitis among school children and the prevalence of oral thrush yeasts, particularly with attention to antifungal drug sensitivity patterns, have contributed meaningfully to pediatric infectious disease management [20, 21]. Oral microbial diseases affecting vulnerable populations, including those with mental, physical, and social disability, represent another dimension of infectious disease burden that deserves more sustained research attention [22].

Antimicrobial resistance remains perhaps the most urgent concern in this space. Bacteria like *Klebsiella pneumoniae* and *Staphylococcus aureus* have developed resistance mechanisms that render multiple drug classes ineffective [23, 24]. Research on *Pseudomonas aeruginosa* antibiotic patterns, particularly with fluoroquinolones, has directly informed clinical treatment protocols in settings where resistance surveillance data was previously limited [25]. Urinary tract infection studies from diverse geographic settings, including Nepal, have similarly highlighted how

resistance profiles vary considerably by region and population [26].

Dental caries microbiology represents yet another important dimension of infectious disease research. Early work isolating and characterizing microbes from dental caries provided foundational data connecting oral microbiome composition to broader systemic disease outcomes [27]. These kinds of community-based, clinically grounded studies remain essential even as the field moves toward more molecularly sophisticated approaches [28, 29].

Viral infections have presented their own distinct set of challenges. The COVID-19 pandemic demonstrated painfully well how unprepared global health systems were for a novel respiratory pathogen [30]. But it also accelerated innovation in vaccine platforms, antiviral drug development, and diagnostic technology at an unprecedented pace [31]. Lessons learned from SARS-CoV-2 are now being applied to preparedness frameworks for future emerging viruses [32].

Tropical and neglected diseases continue to impose enormous burdens in low- and middle-income countries. Research documenting seizure prevalence and risk factors in stage-2 rhodesiense human African trypanosomiasis in Zambia is a sobering reminder that some ancient diseases remain poorly controlled and inadequately researched [33]. These studies bridge clinical observation and epidemiology in exactly the way translational research demands.

3. The HPV-HIV Intersection: A Case Study in Translational Infectious Disease Research

Few areas illustrate the translational potential of infectious disease research more clearly than the intersection of human papillomavirus and HIV. Women living with HIV face dramatically elevated risks of HPV infection and cervical cancer progression, creating a clinical problem that sits squarely at the boundary between virology, immunology, and oncology [34, 35].

Investigations into HPV infection among HIV-positive women, including early work documenting HPV prevalence in women with HIV type-1 and subsequent studies specifically characterizing HPV type 16 in AIDS patients, established an important clinical and epidemiological foundation [36, 37]. Follow-up research confirming HPV type 16 prevalence in HIV-positive women reinforced the need for integrated screening and prevention strategies that address both infections simultaneously [38, 39].

These studies are not merely descriptive. They directly support the case for HPV vaccination programs in HIV-endemic regions and highlight the need for cervical cancer screening protocols that are responsive to immunocompromised populations [40, 41]. The translational pathway here runs from community-level prevalence data through molecular virology to clinical policy, which is precisely the journey that defines this field at its best.

4. Cancer Biology: Understanding the Enemy From Within

Cancer is not one disease. That sounds simple, but it took decades of molecular research to really absorb what it means. Tumors that look identical under a microscope can behave completely differently, respond to opposite treatments, and arise from entirely distinct genetic events [42, 43]. Understanding that heterogeneity has become one of the central challenges of modern oncology.

The shift toward precision medicine has been transformative. Rather than treating breast cancer or lung cancer as monolithic categories, oncologists now increasingly target specific mutations, protein expressions, and signaling pathway dysregulations [44, 45]. Drugs like imatinib and trastuzumab demonstrated early on that molecularly targeted therapy could achieve remarkable outcomes even in previously refractory disease [46].

Cervical cancer has attracted particular research attention given its strong viral etiology. In vitro cytotoxic evaluation of plant extracts against SiHa cervical cancer cells, including work with *Euphorbia hirta* L. involving phytochemical screening, GC-MS, and FT-IR metabolite profiling, has contributed both mechanistic and applied insights into how plant-derived compounds might be leveraged against virally driven cancers [47]. Related work evaluating *Achyranthesaspera* methanol extracts for antioxidant and anticancer activity in SiHa cells further expanded the plant-based arsenal against cervical cancer [48]. Breast cancer research has similarly benefited from phytochemical investigation. Anticancer activity studies of *Ficus carica* L. on MCF-7 human breast cancer cells demonstrated cytotoxic potential that warrants further mechanistic exploration [49]. More recently, computational evaluation of linezolid and ciprofloxacin targeting the mutant ESR1 protein in breast cancer represented an innovative drug repurposing approach, applying known antimicrobial agents to an oncological problem through in silico methods [50].

Tumor microenvironment research has added another layer of complexity to our understanding of cancer. Cancer cells do not exist in isolation; they actively recruit immune cells, remodel surrounding tissue, and create conditions that suppress antitumor immunity [51, 52]. Immunotherapy, particularly immune checkpoint blockade, has exploited this understanding to produce durable responses in cancers that once carried very poor prognoses [53]. Still, not every patient responds, and understanding why remains an active and somewhat humbling area of investigation.

Epigenetic alterations have also emerged as major players in cancer development and progression. DNA methylation patterns, histone modifications, and non-coding RNA expression all contribute to how cancer cells regulate gene expression in ways that differ fundamentally from normal cells [54, 55]. These mechanisms are increasingly recognized as therapeutic targets in their own right, opening new avenues that complement

existing chemotherapy and immunotherapy approaches.

5. Phytomedicine: When Traditional Knowledge Meets Modern Science

There is something intellectually satisfying about watching traditional plant remedies hold up under rigorous scientific scrutiny. Phytomedicine has traveled a long road from folk wisdom to peer-reviewed biochemistry, and that journey is still very much underway [56, 57]. Plants produce an extraordinary diversity of secondary metabolites, compounds they make not for nutrition but largely for defense, and many of these turn out to have remarkable biological activity in human systems. Some of the most important drugs in modern medicine originated from plants. Taxol from the Pacific yew tree, artemisinin from *Artemisia annua*, and morphine from the opium poppy all began as traditional remedies before becoming pharmaceutical mainstays [58, 59]. These examples are not historical curiosities; they are proof of concept for the entire field.

Boerhaaviadiffusa has emerged as a particularly interesting subject of phytomedicinal research. Early in vitro anticancer activity studies demonstrated meaningful cytotoxic potential against cancer cell lines [60], and subsequent in vitro cytotoxic analysis provided further evidence of this plant's bioactive profile [61]. These experimental findings laid the groundwork for more sophisticated computational investigations, including 3D peptide-protein docking studies exploring interactions between novel *Boerhaviadiffusa*-derived peptides and the cervical cancer-associated transmembrane protein TM50A [62]. A parallel in silico investigation further identified a novel peptide derived from *Boerhaviadiffusa* targeting β -lactamase TEM of *Klebsiellapneumoniae*, elegantly bridging phytomedicine and antimicrobial resistance research [63].

Ipomoea obscura represents another plant whose potential has been systematically characterized. Phytochemical constituent analysis alongside assessment of crude extracts for antioxidant, anti-inflammatory, antibacterial, and anticancer activities provided a comprehensive pharmacological profile that supports further drug development work [64]. Similarly, biosynthesized silver nanoparticles from *Terminaliachebula* were evaluated for antioxidant and antifungal activities, illustrating how phytomedicine and nanotechnology are converging in productive ways [65].

The antibacterial potential of *Tephrosiapurpurea* extracts against tomato spoilage pathogens bridges agricultural and human health applications, showing that phytomedicinal research has implications well beyond the clinic [66]. Production of oleic acid from mango kernel waste using probiotic bacteria isolated from marine fishes represents another creative intersection of natural product chemistry and biotechnology [67].

Contemporary phytomedicine research has become far more sophisticated overall. Researchers are now isolating and characterizing specific bioactive compounds, testing them in cell lines and animal models, and using molecular docking studies to understand exactly how they interact with biological targets [68, 69]. Flavonoids, alkaloids, terpenes, and phenolic acids are among the compound classes attracting the most attention, particularly for their anticancer, antimicrobial, and anti-inflammatory properties [70, 71]. One area generating considerable excitement is the potential of plant compounds to overcome drug resistance. Some phytochemicals appear to sensitize resistant cancer cells or bacteria to conventional treatments, essentially restoring therapeutic efficacy that had been lost [72, 73]. That kind of synergistic interaction is exactly what translational research is designed to discover and develop.

Table 1: Major Bioactive Plant Compounds and Their Therapeutic Targets

Compound	Plant Source	Biological Activity	Molecular Target	Current Status
Curcumin	<i>Curcuma longa</i>	Anticancer, Anti-inflammatory	NF-κB, STAT3, Bcl-2	Clinical trials
Artemisinin	<i>Artemisia annua</i>	Antimalarial, Anticancer	Heme, ROS generation	Approved (malaria)
Resveratrol	<i>Vitisvinifera</i>	Antioxidant, Anticancer	Sirtuins, p53, COX	Preclinical/trials
Quercetin	<i>Allium cepa</i>	Antimicrobial, Antiviral	PI3K, Caspases	Preclinical
Berberine	<i>Berberis</i> spp.	Antimicrobial, Anticancer	AMPK, DNA gyrase	Clinical trials
Taxol (Paclitaxel)	<i>Taxusbrevifolia</i>	Anticancer	Microtubule stabilization	FDA approved
Boerhaavine	<i>Boerhaaviadiffusa</i>	Anticancer, Antimicrobial	TM50A, β-Lactamase TEM	In silico/In vitro [60, 62, 63]
EGCG	<i>Camellia sinensis</i>	Antioxidant, Anticancer	EGFR, VEGF, Bcl-2	Preclinical/trials

6. Bioinformatics: Making Sense of Biological Complexity

Biology generates data at a scale that would have seemed absurd twenty years ago. A single genomic sequencing run produces gigabytes of raw information, and when you multiply that across thousands of samples, patients, or experimental conditions, the numbers become genuinely staggering [74, 75]. Bioinformatics exists precisely because biology outgrew what human minds could process unaided. At its core, bioinformatics is about developing and applying computational methods to understand biological systems. It encompasses sequence analysis, structural prediction, network modeling, and increasingly, machine learning approaches that can identify patterns invisible to conventional analysis [76, 77]. Tools like BLAST, ClustalW, and AutoDock have become as fundamental to biomedical research as the pipette or the microscope.

In silico drug discovery and peptide design have proven particularly valuable in recent years. Research identifying novel peptides targeting *Anopheles gambiae* using in silico approaches represents a meaningful advance in computational vector biology, with direct implications for malaria control [78]. Peptide-based medicines against *Aedes aegypti* identified through in silico techniques similarly demonstrate the power of computational approaches in developing new tools against mosquito-borne diseases [79]. Parallel work discovering novel peptides against *Culex quinquefasciatus* extended this computational framework to another major disease vector [80].

Drug repurposing through computational methods has opened another productive avenue. The investigation of tramadol hydrochloride's impact on *Staphylococcus aureus* multidrug export protein MepA using in silico chemical repurposing methods is a creative example of how

existing drugs might find new applications in combating antimicrobial resistance [81]. This approach is particularly valuable given the enormous costs and timelines associated with developing entirely new drugs from scratch.

The intersection of nanotechnology and environmental science has also benefited from computational and analytical frameworks. Published work on nanomaterials in environmental pollution and sustainable advanced technologies reflects the broader context in which biomedical research now operates, recognizing that environmental factors profoundly shape infectious disease dynamics and human health outcomes [82]. For cancer biology, multi-omics integration combining genomics, transcriptomics, proteomics, and metabolomics data has revealed molecular subtypes within cancers that were previously indistinguishable [83, 84]. These subtypes often have different prognoses and respond differently to treatment, which has direct clinical implications. The Cancer Genome Atlas and similar projects have made enormous datasets publicly available, accelerating discovery considerably [85].

In infectious disease research, bioinformatics has enabled rapid pathogen identification, phylogenetic tracing of outbreaks, and prediction of drug resistance mutations from sequence data alone [86, 87]. During the COVID-19 pandemic, real-time genomic surveillance became essential infrastructure for understanding viral evolution and variant emergence [88]. In phytomedicine, computational approaches have become indispensable for screening large chemical libraries against disease-relevant protein targets [89, 90]. Virtual screening and molecular dynamics simulations allow researchers to prioritize compounds before expensive and time-consuming laboratory work begins, making drug discovery from plant sources considerably more efficient.

Table 2: Summary of Key InSilico Studies in Infectious Disease and Cancer Research

Study Focus	Target Organism/Disease	Method Used	Key Finding
Peptide docking against TM50A	Cervical cancer	3D peptide-protein docking	Novel <i>B. diffusa</i> peptide binds TM50A
Linezolid/Ciprofloxacin vs ESR1	Breast cancer	Molecular docking	Drug repurposing potential confirmed
Novel peptides vs <i>A. gambiae</i>	Malaria vector	In silico peptide design	Potent binding peptides identified
Tramadol vs MepA	<i>S. aureus</i> AMR	Chemical repurposing	Anti-efflux activity predicted
Peptide vs <i>Aedes aegypti</i>	Dengue/Zika vector	In silico screening	Novel peptide medicine identified
Peptide vs <i>Culex quinquefasciatus</i>	West Nile/Filariasis vector	Computational docking	De novo peptide candidate found
<i>B. diffusa</i> peptide vs β -Lactamase TEM	<i>K. pneumoniae</i> AMR	In silico docking	Resistance enzyme inhibition predicted

7. The Convergence: Where These Fields Intersect

The most exciting science today seems to happen at intersections. When bioinformatics tools are applied to phytochemical databases, or when cancer biology frameworks are used to understand oncogenic viruses, or when antimicrobial resistance patterns are analyzed using network approaches, something genuinely new tends to emerge [91, 92].

Network pharmacology represents one of the clearest examples of this convergence. Rather than studying single compounds against single targets, network pharmacology maps the complex relationships between multiple phytochemicals and multiple disease-associated proteins simultaneously [93, 94]. This systems-level thinking acknowledges that diseases are rarely driven by a single molecular event and that effective therapies might need to act on several nodes of a biological network at once. The body of work reviewed here embodies this convergence

beautifully. A single research program moving from in vitro anticancer screening of plant extracts through in silico peptide docking studies to computational antimicrobial peptide discovery and drug repurposing represents exactly the kind of integrated, multi-modal approach that modern translational research demands [60, 61, 62, 78, 79, 80, 81]. The tools change, the questions evolve, but the commitment to connecting laboratory findings with clinical relevance remains constant.

Cancer virology illustrates yet another kind of convergence. Viruses like human papillomavirus, Epstein-Barr virus, and hepatitis B virus are well-established oncogenic agents, and understanding their biology has produced some of the most effective cancer prevention tools available, namely vaccines [95, 96]. Research into how these viruses manipulate host cell machinery continues to reveal cancer biology insights that extend well beyond virally driven tumors. The body of HPV-HIV co-infection research reviewed earlier contributes directly to this intersection of virology and oncology [36, 37, 38, 39].

8. Challenges and Future Directions


No honest review of this field would skip over the difficulties. Translational research is genuinely hard. Many compounds that look promising in cell culture fail in animal models, and many that work in animals never make it through clinical trials [97, 98]. The gap between a laboratory finding and an approved therapy is wide, expensive, and littered with promising ideas that did not survive contact with biological complexity.

Standardization remains a persistent problem in phytomedicine specifically. Plant material varies considerably depending on geographical origin, harvesting season, and processing methods, which makes reproducibility challenging [99, 100]. Regulatory frameworks have not always kept pace with the research, creating uncertainty about how plant-based therapeutics should be evaluated

and approved. Aging and comorbidity add further complexity to translational research. A cross-sectional study examining the impact of aging on orthostatic hypotension and mental health reflects how the patient population receiving these therapies is itself changing in important ways. Translational research cannot focus exclusively on molecular mechanisms while ignoring the physiological and social contexts in which patients actually live.

Looking forward, the integration of artificial intelligence with multi-omics data holds extraordinary promise. Models that can predict drug responses, identify resistance mechanisms before they emerge clinically, or match patients to therapies based on molecular profiles could genuinely transform medicine. But that future depends on better data, better validation frameworks, and more genuine collaboration across disciplines than currently exists.

Figure 1: Conceptual Framework of Translational Biomedical Research Convergence



9. Conclusion

Translational biomedical research is not a single field so much as a philosophy, a commitment to ensuring that scientific knowledge actually reaches and helps people. The four domains explored in this review, infectious diseases, cancer biology, phytochemistry, and bioinformatics, are each impressive individually. But their real potential seems to emerge when researchers stop treating disciplinary boundaries as walls and start treating them as invitations to collaborate. The body of work reviewed here, spanning community-level epidemiology of parasitic and fungal infections, HPV-HIV co-infection research, plant-based anticancer and antimicrobial investigations, biosynthesis and nanotechnology, and sophisticated in silico drug and peptide discovery, illustrates how a coherent translational research program can span multiple disciplines over time without losing scientific rigor or clinical relevance. The tools available today are genuinely extraordinary. Genomic sequencing, computational modeling, high-throughput screening, and systems biology approaches have created opportunities that simply did not exist a generation ago. What is needed now is the scientific culture and institutional infrastructure to make use of them wisely, funding interdisciplinary work, training scientists who can move comfortably across fields, and maintaining the patience that genuine translation requires. Progress is real and worth celebrating, but so are the gaps, and acknowledging them honestly is part of what makes research credible and trustworthy.

Acknowledgment

The author extends her appreciation to the management of Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, for encouraging this work.

Conflict of interest

The author disclose no conflicts of interest.

References

1. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249. <https://doi.org/10.3322/caac.21660>
2. Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., & Naghavi, M. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. *The Lancet*, 399(10325), 629–655. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)
3. Venkatajothi, R. (2017). In vitro anti-cancer activity of *Boerhaaviadiffusa* Linn. *International Journal of Current Research in Biological Medicine*, 2(3), 20–24.
4. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. *Journal of Natural Products*, 83(3), 770–803. <https://doi.org/10.1021/acs.jnatprod.9b01285>
5. World Health Organization. (2024). *Global health estimates: Leading causes of death*. WHO Press.
6. Venkatajothi, R. (2017). Incidence of intestinal protozoa infections among school going children. *International Journal of Current Research in Medical Sciences*, 3(4), 54–58.
7. Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., & Argemi, X. (2018). Discovery, research, and development of new antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis. *The Lancet Infectious Diseases*, 18(3), 318–327. [https://doi.org/10.1016/S1473-3099\(17\)30753-3](https://doi.org/10.1016/S1473-3099(17)30753-3)
8. Vasan, N., Baselga, J., & Hyman, D. M. (2019). A view on drug resistance in cancer. *Nature*, 575(7782), 299–309. <https://doi.org/10.1038/s41586-019-1730-1>

9. Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E. M., Linder, T., Wawrosch, C., Uhrin, P., & Dirsch, V. M. (2015). Discovery and resupply of pharmacologically active plant-derived natural products: A review. *Biotechnology Advances*, 33(8), 1582–1614.
10. Venkatajothi, R., & Vinod Kumar, C. S. (2011). Human papilloma virus infection in women with the human immunodeficiency virus type-1. *International Journal of Biological and Medical Research*, 2(3), 771–774.
11. Zou, J., Huss, M., Abid, A., Mohammadi, P., Torkamani, A., & Telenti, A. (2019). A primer on deep learning in genomics. *Nature Genetics*, 51(1), 12–18. <https://doi.org/10.1038/s41588-018-0295-5>
12. Hopkins, A. L. (2008). Network pharmacology: The next paradigm in drug discovery. *Nature Chemical Biology*, 4(11), 682–690. <https://doi.org/10.1038/nchembio.118>
13. Venkatajothi, R. (2010). Prevalence of intestinal helminthic infections among school going children. *International Journal of Current Research in Biological Medicine*, 2(1), 33–38.
14. Shen, B. (2015). A new golden age of natural products drug discovery. *Cell*, 163(6), 1297–1300. <https://doi.org/10.1016/j.cell.2015.11.031>
15. Morens, D. M., & Fauci, A. S. (2020). Emerging pandemic diseases: How we got to COVID-19. *Cell*, 182(5), 1077–1092. <https://doi.org/10.1016/j.cell.2020.08.021>
16. Venkatajothi, R. (2017). Clinicomycological study of tineacapitis infections among school children. *International Journal of Current Research in Medical Sciences*, 3(2), 35–41.
17. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. *Cell*, 144(5), 646–674. <https://doi.org/10.1016/j.cell.2011.02.013>
18. Piret, J., & Boivin, G. (2021). Pandemics throughout history. *Frontiers in Microbiology*, 11, 631736. <https://doi.org/10.3389/fmicb.2020.631736>
19. Venkatajothi, R., Rajendran, P., Vinod Kumar, C. S., Nivedha, R., & Melani Rajendran. (2011). Oral microbial diseases and care for people with mental, physical and social disability. *International Journal of Applied Microbiology*, 14(1), 1–8.
20. Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. *The Lancet Infectious Diseases*, 20(5), 533–534. [https://doi.org/10.1016/S1473-3099\(20\)30120-1](https://doi.org/10.1016/S1473-3099(20)30120-1)
21. Iwasaki, A., & Medzhitov, R. (2015). Control of adaptive immunity by the innate immune system. *Nature Immunology*, 16(4), 343–353. <https://doi.org/10.1038/ni.3123>
22. Venkatajothi, R., Shanthi, J., Jaikumar, S., Arumugam, S., Nivedha, R., MelaniRajendran, S., & Rajendran, P. (2002). Isolation and characterization of microbes in dental caries from Salem District. *International Journal of Applied Microbiology*, 2(1), 57–58.
23. Gardy, J. L., & Loman, N. J. (2018). Towards a genomics-informed, real-time, global pathogen surveillance system. *Nature Reviews Genetics*, 19(1), 9–20. <https://doi.org/10.1038/nrg.2017.88>
24. Laxminarayan, R., Duse, A., Wattal, C., Zaidi, A. K., Wertheim, H. F., Sumpradit, N., & Cars, O. (2013). Antibiotic resistance: The need for global solutions. *The Lancet*, 382(9912), 1057–1098. [https://doi.org/10.1016/S0140-6736\(13\)60854-0](https://doi.org/10.1016/S0140-6736(13)60854-0)
25. Venkatajothi, R., Rajagopal, G., & Vinod Kumar, C. S. (2010). Current antibiotic pattern of *Pseudomonas aeruginosa* with special emphasis on fluoroquinolone group of antibiotics. *Biomedicine*, 30(4), 515–520.
26. Venkatajothi, R., Rajendran, P., & Ashok, G. (2006). Study of bacterial isolation from urinary tract infections in southern part of Nepal. *International Journal of Applied Microbiology*, 6(1), 1–3.

27. Venkatajothi Ramarao, Seethalakshmi Illanchezian. Studies on Preliminary Phytochemical Screening and In Vitro Antibacterial Activities of *Euphorbia hirta*. *Int. J. Adv. Res.* 2023, 10 (7): 57-62.
28. Underhill, D. M., & Goodridge, H. S. (2012). Information processing during phagocytosis. *Nature Reviews Immunology*, 12(7), 492–502. <https://doi.org/10.1038/nri3244>
29. Gordillo Altamirano, F. L., & Barr, J. J. (2019). Phage therapy in the postantibiotic era. *Clinical Microbiology Reviews*, 32(2), e00066-18. <https://doi.org/10.1128/CMR.00066-18>
30. Krammer, F. (2020). SARS-CoV-2 vaccines in development. *Nature*, 586(7830), 516–527. <https://doi.org/10.1038/s41586-020-2798-3>
31. Venkatajothi, R. (2017). Prevalence of oral thrush yeasts among school children with special emphasis of fluconazole antifungal drug. *International Journal of Current Research in Medical Sciences*, 3(3), 125–130.
32. Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2022). Universal coronavirus vaccines: An urgent need. *New England Journal of Medicine*, 386(4), 297–299. <https://doi.org/10.1056/NEJMp2118468>
33. Victor Mwanakasale, Venkatajothi, R., & Mwaba Mwansa. (2023). Prevalence and risk factors for seizures in stage-2 of rhodesiense human African trypanosomiasis in Zambia from January 2013 to July 2022. *International Journal of Current Innovative Advanced Research*, 5(4), 1–4.
34. Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S. (2007). Human papillomavirus and cervical cancer. *The Lancet*, 370(9590), 890–907. [https://doi.org/10.1016/S0140-6736\(07\)61416-0](https://doi.org/10.1016/S0140-6736(07)61416-0)
35. Clifford, G. M., Goncalves, M. A., & Franceschi, S. (2006). Human papillomavirus types among women infected with HIV: A meta-analysis. *AIDS*, 20(18), 2337–2344. <https://doi.org/10.1097/QAD.0b013e32801022ab>
36. Venkatajothi, R., & Vinod Kumar, C. S. (2010). Prevalence of human papilloma virus type 16 in AIDS women. *Biomedicine*, 30(2), 134–138.
37. Venkatajothi, R., Vinod Kumar, C. S., & Seethalakshmi Illanchezian. (2023). Human papillomavirus type 16 in HIV women. *International Journal of Current Research in Medical Sciences*, 9(6), 1–6.
38. Venkatajothi, R., Vinod Kumar, C. S., & Rajendran, P. (2011). Screening of high risk human papilloma virus type 16 in AIDS women. *Biomedicine*, 31(3), 302–306.
39. De Vuyst, H., Clifford, G. M., Nascimento, M. C., Madeleine, M. M., & Franceschi, S. (2009). Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. *International Journal of Cancer*, 124(7), 1626–1636. <https://doi.org/10.1002/ijc.24116>
40. Kartheek R. Balapala, Mwanakasale, V., Mukanga, B., Venkatajothi Ramarao, Silitongo, M. S., Sayana, S. B., & Mushabati, F. (2025). Impact of ageing on orthostatic hypotension and mental health: A cross-sectional study. *Romanian Medical Journal*, 72(1). <https://doi.org/10.37897/RMJ.2025.1.7>
41. Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., & Muñoz, N. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. *Journal of Pathology*, 189(1), 12–19. [https://doi.org/10.1002/\(SICI\)1096-9896\(199909\)189:1<12::AID-PATH431>3.0.CO;2-F](https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F)
42. Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013). Cancer genome landscapes. *Science*, 339(6127), 1546–1558. <https://doi.org/10.1126/science.1235122>
43. Hanahan, D. (2022). Hallmarks of cancer: New dimensions. *Cancer Discovery*, 12(1), 31–46. <https://doi.org/10.1158/2159-8290.CD-21-1059>

44. Tsimberidou, A. M. (2015). Targeted therapy in cancer. *Cancer Chemotherapy and Pharmacology*, 76(6), 1113–1132. <https://doi.org/10.1007/s00280-015-2861-1>
45. Venkatajothi Ramarao, & Vijayalakshmi, K. (2026). Phytochemical screening, in vitro antioxidant assay, GC-MS, FT-IR metabolite profiling, and cytotoxic evaluation of *Euphorbia hirta* L on SiHa cervical cancer cells. *Journal of Community Health Research*, 16(2), 38–50. <https://www.jchr.org/index.php/JCHR/article/view/12281/6696>
46. Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., & Larson, R. A. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. *New England Journal of Medicine*, 355(23), 2408–2417. <https://doi.org/10.1056/NEJMoa062867>
47. Venkatajothi Ramarao, & Seethalakshmi Illanchezian. (2023). Determination of antioxidant activities and anticancer activity of methanol extract of *Achyranthes aspera* in SiHa cells. *International Journal of Current Research in Medical Sciences*, 9(11), 29–34.
48. Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., & Schultz, N. (2017). OncoKB: A precision oncology knowledge base. *JCO Precision Oncology*, 1, 1–16. <https://doi.org/10.1200/PO.17.00011>
49. Venkatajothi Ramarao, Seethalakshmi Illanchezian, & Amudha, C. (2024). Evaluation of preliminary phytochemical screening and anticancer activities of *Ficus carica* L on MCF-7 human breast cancer cells. *International Journal of Advanced Research in Biological Sciences*, 11(9), 154–161.
50. Ramarao Venkatajothi. (2026). Computational evaluation of linezolid and ciprofloxacin targeting mutant ESR1 protein in breast cancer. *Research Journal of Biotechnology*, 21(7), 205–210. <https://doi.org/10.25303/217rjbt2050210>
51. Fridman, W. H., Zitvogel, L., Sautès-Fridman, C., & Kroemer, G. (2017). The immune contexture in cancer prognosis and treatment. *Nature Reviews Clinical Oncology*, 14(12), 717–734. <https://doi.org/10.1038/nrclinonc.2017.101>
52. Ribas, A., & Wolchok, J. D. (2018). Cancer immunotherapy using checkpoint blockade. *Science*, 359(6382), 1350–1355. <https://doi.org/10.1126/science.aar4060>
53. Venkatajothi Ramarao, & Seethalakshmi Illanchezian. (2023). In vitro cytotoxic analysis of *Boerhaavia diffusa* Linn. *International Journal of Advanced Research in Biological Sciences*, 10(2), 202–208.
54. Jones, P. A., Issa, J. P., & Baylin, S. (2016). Targeting the cancer epigenome for therapy. *Nature Reviews Genetics*, 17(10), 630–641. <https://doi.org/10.1038/nrg.2016.93>
55. Esteller, M. (2008). Epigenetics in cancer. *New England Journal of Medicine*, 358(11), 1148–1159. <https://doi.org/10.1056/NEJMra072067>
56. Fabricant, D. S., & Farnsworth, N. R. (2001). The value of plants used in traditional medicine for drug discovery. *Environmental Health Perspectives*, 109(Suppl 1), 69–75. <https://doi.org/10.1289/ehp.01109s169>
57. Venkatajothi Ramarao, Athiappan, M., Mwanakasale, V., Subramanian, B., Balapala, K. R., & Amudha, C. (2025). Phytochemical constituents and assessment of crude extracts from *Ipomoea obscura* for antioxidant, anti-inflammatory, antibacterial and anti-cancer activities. *Research Journal of Pharmacy and Technology*, 18(5), 2297–2304. <https://doi.org/10.52711/0974-360X.2025.00329>
58. Cragg, G. M., & Newman, D. J. (2013). Natural products: A continuing source of novel drug leads. *Biochimica et Biophysica Acta*, 1830(6), 3670–3695. <https://doi.org/10.1016/j.bbagen.2013.02.008>
59. Tu, Y. (2016). Artemisinin: A gift from traditional Chinese medicine to the world (Nobel lecture). *Angewandte Chemie International Edition*, 55(35), 10210–10226. <https://doi.org/10.1002/anie.201601967>

60. Venkatajothi Ramarao, Selvam Periaswamy, & Madhu Bala Selvam. (2025). Identification of a novel peptide-based medicine derived from *Boerhavia diffusa* against β -lactamase TEM of *Klebsiella pneumoniae* using in silico approaches. *UPJOZ*, 46(10), 385–393. <https://doi.org/10.56557/upjoz/2025/v46i104997>
61. Venkatajothi Ramarao, & Balaji Munivelan. (2025). 3D peptide–protein docking between a novel peptide derived from *Boerhavia diffusa* and a cervical cancer protein, transmembrane protein 50A (TM50A), using in silico strategies. *International Journal of Applied Research*, 11(2), 293–298. <https://doi.org/10.22271/allresearch.2025.v11.i2d.12376>
62. Panche, A. N., Diwan, A. D., & Chandra, S. R. (2016). Flavonoids: An overview. *Journal of Nutritional Science*, 5, e47. <https://doi.org/10.1017/jns.2016.41>
63. Wink, M. (2015). Modes of action of herbal medicines and plant secondary metabolites. *Medicines*, 2(3), 251–286. <https://doi.org/10.3390/medicines2030251>
64. Venkatajothi Ramarao, Selvam, P., & Amudha, C. (2024). *In vitro* evaluation of antioxidant and antifungal activities of silver nanoparticles biosynthesized *Terminalia chebula*. *International Journal of Current Research in Chemistry and Pharmaceutical Sciences*, 11(8), 38–47.
65. K. Vijayalakshmi, Mohamed Mahroop Raja, M., Venkatajothi Ramarao, Sivamanikandan, P., PriyaDharsini, P., Winny Fred Crossia, A., Sowndarya Sivaprakasam, & Sivagami Varadharajan. (2025). Exploring the antibacterial potential of *Tephrosia purpurea* extracts against tomato spoilage pathogens. *Journal of Community Health Research*, 15(3), 1052–1061. <https://www.jchr.org/index.php/JCHR/article/view/8391/4793>
66. Tungmunnithum, D., Thongboonyou, A., Pholboon, A., & Yangsabai, A. (2018). Flavonoids and other phenolic compounds from medicinal plants for pharmaceutical and medical aspects: An overview. *Medicines*, 5(3), 93. <https://doi.org/10.3390/medicines5030093>
67. Rubavathi Anandan, Visali Kannan, Lavanya Sivakumar, Venkatajothi Ramarao, & Athiappan, M. (2024). Production of oleic acid from mango kernels waste using probiotic bacteria isolated from marine fishes. *Asian Journal of Chemistry*, 36(7), 1511–1517. <https://doi.org/10.14233/ajchem.2024.31515>
68. Baell, J. B., & Walters, M. A. (2014). Chemistry: Chemical con artists foil drug discovery. *Nature*, 513(7519), 481–483. <https://doi.org/10.1038/513481a>
69. Venkatajothi Ramarao, Yamini Sudhalakshmi, Athiappan, M., Vijayalakshmi Kandasamy, & Yavanika, V. (2025). Impact of the anti-inflammatory medication tramadol hydrochloride on *Staphylococcus aureus* multidrug export protein MepA using in silico chemical repurposing methods. *Journal of Zoological Investigations*, 11(1), 610–619. <https://doi.org/10.33745/ijzi.2025.v11i01.064>
70. Efferth, T., & Koch, E. (2011). Complex interactions between phytochemicals: The multi-target therapeutic concept of phytotherapy. *Current Drug Targets*, 12(1), 122–132. <https://doi.org/10.2174/138945011793591626>
71. Kumaran Subramanian, Santhosh Kumar, A. W., Rajesh, R. P., & Venkatajothi Ramarao. (2024). Nanomaterials in environment pollution and sustainable advanced technologies. *Environmental Science and Pollution Research*, 31, 67315–67316. <https://doi.org/10.1007/s11356-024-35372-6>
72. Cheung-Ong, K., Giaever, G., & Nislow, C. (2013). DNA-damaging agents in cancer chemotherapy: Serendipity and chemical biology. *Chemistry and Biology*, 20(5), 648–659. <https://doi.org/10.1016/j.chembiol.2013.04.007>
73. Venkatajothi Ramarao, Selvam Periaswamy, & Madhu Bala Selvam. (2025). Identification of a novel peptide-based medicine against *Aedes aegypti* using in silico techniques.

- Indian Journal of Mosquito Research*, 12(3), 27–31.
<https://doi.org/10.22271/23487941.2025.v12.i3a.837>
74. Stephens, Z. D., Lee, S. Y., Faghri, F., Campbell, R. H., Zhai, C., Efron, M. J., & Robinson, G. E. (2015). Big data: Astronomical or genetical? *PLOS Biology*, 13(7), e1002195.
<https://doi.org/10.1371/journal.pbio.1002195>
75. Venkatajothi Ramarao, Mohamed Mahroop Raja, M., & Vijayalakshmi Kandasamy. (2025). Discovery of a de novo medicine derived from peptide against *Culex quinquefasciatus* using computational protocols. *Indian Journal of Mosquito Research*, 12(3), 32–36.
<https://doi.org/10.22271/23487941.2025.v12.i3a.838>
76. Libbrecht, M. W., & Noble, W. S. (2015). Machine learning applications in genetics and genomics. *Nature Reviews Genetics*, 16(6), 321–332. <https://doi.org/10.1038/nrg3920>
77. Venkatajothi Ramarao, Natarajan, K., Rubina Mary, A., Venkatesan, S., Subramanian, B., & Yokesh, V. (2026). Discovery of novel peptides targeting *Anopheles gambiae* using in silico approaches. *International Journal of Drug Delivery Technology*, 16(3), 132–139.
<https://doi.org/10.25258/ijddt.16.3.17>
78. Trott, O., & Olson, A. J. (2010). AutoDockVina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of Computational Chemistry*, 31(2), 455–461.
<https://doi.org/10.1002/jcc.21334>
79. Elbe, S., & Buckland-Merrett, G. (2017). Data, disease and diplomacy: GISAID's innovative contribution to global health. *Global Challenges*, 1(1), 33–46.
<https://doi.org/10.1002/gch2.1018>
80. Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., & Ideker, T. (2003). Cytoscape: A software environment for integrated models of biomolecular interaction networks. *Genome Research*, 13(11), 2498–2504.
<https://doi.org/10.1101/gr.1239303>
81. Venkatajothi Ramarao, Murugan Athiappan, Rajasekar Thirunavukkarasu, M. Mohamed Mahroop Raja, Vijayalakshmi Kandasamy. Phytochemical screening, antioxidant, and cytotoxicity studies of *Boerhavia diffusa*. *Int. J. Biosci*, 2025, Vol. 26, No. 4, p. 144-152.
82. Tomczak, K., Czerwińska, P., & Wiznerowicz, M. (2015). The Cancer Genome Atlas (TCGA): An immeasurable source of knowledge. *Contemporary Oncology*, 19(1A), A68–A77.
<https://doi.org/10.5114/wo.2014.47136>
83. Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., & Mesirov, J. P. (2005). Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences*, 102(43), 15545–15550.
<https://doi.org/10.1073/pnas.0506580102>
84. Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R., Ozenberger, B. A., Ellroth, K., & Stuart, J. M. (2013). The Cancer Genome Atlas pan-cancer analysis project. *Nature Genetics*, 45(10), 1113–1120.
<https://doi.org/10.1038/ng.2764>
85. Kwong, J. C., Mercouliou, K., Tomita, T., Easton, M., Li, H. Y., Bulach, D. M., & Howden, B. P. (2016). Prospective whole-genome sequencing enhances national surveillance of *Listeria monocytogenes*. *Journal of Clinical Microbiology*, 54(2), 333–342.
<https://doi.org/10.1128/JCM.02344-15>
86. Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., & Bedford, T. (2018). Nextstrain: Real-time tracking of pathogen evolution. *Bioinformatics*, 34(23), 4121–4123.
<https://doi.org/10.1093/bioinformatics/bty407>
87. Dallakyan, S., & Olson, A. J. (2015). Small-molecule library screening by docking with PyRx. *Methods in Molecular Biology*, 1263, 243–250. https://doi.org/10.1007/978-1-4939-2269-7_19
88. Barabási, A. L., Gulbahce, N., & Loscalzo, J. (2011). Network medicine: A network-based approach to human disease. *Nature Reviews*

- Genetics*, 12(1), 56–68.
<https://doi.org/10.1038/nrg2918>
92. Li, S., & Zhang, B. (2013). Traditional Chinese medicine network pharmacology: Theory, methodology and application. *Chinese Journal of Natural Medicines*, 11(2), 110–120. [https://doi.org/10.1016/S1875-5364\(13\)60037-0](https://doi.org/10.1016/S1875-5364(13)60037-0)
93. Zur Hausen, H. (2009). Papillomaviruses in the causation of human cancers: A brief historical account. *Virology*, 384(2), 260–265.
<https://doi.org/10.1016/j.virol.2008.11.046>
94. Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? *Nature Reviews Drug Discovery*, 3(8), 711–716. <https://doi.org/10.1038/nrd1470>
95. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014). Clinical development success rates for investigational drugs. *Nature Biotechnology*, 32(1), 40–51.
<https://doi.org/10.1038/nbt.2786>
96. Heinrich, M., Appendino, G., Efferth, T., Fürst, R., Izzo, A. A., Kayser, O., Pezzuto, J. M., & Viljoen, A. (2020). Best practice in research: Overcoming common challenges in phytopharmacological research. *Journal of Ethnopharmacology*, 246, 112230. <https://doi.org/10.1016/j.jep.2019.112230>
97. Fried, L. P., Tangen, C. M., Walston, J., Newman, A. B., Hirsch, C., Gottdiener, J., & McBurnie, M. A. (2001). Frailty in older adults: Evidence for a phenotype. *Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, 56(3), M146–M157. <https://doi.org/10.1093/gerona/56.3.M146>
98. Petersen, P. E. (2003). The world oral health report 2003: Continuous improvement of oral health in the 21st century. *Community Dentistry and Oral Epidemiology*, 31(Suppl 1), 3–24.
<https://doi.org/10.1046/j..2003.com122.x>
99. Socransky, S. S., & Haffajee, A. D. (2005). Periodontal microbial ecology. *Periodontology 2000*, 38(1), 135–187. <https://doi.org/10.1111/j.1600-0757.2005.00107.x>
100. Nel, A., Xia, T., Mädler, L., & Li, N. (2006). Toxic potential of materials at the nanolevel. *Science*, 311(5761), 622–627. <https://doi.org/10.1126/science.1114397>

Access this Article in Online	
	Website: www.ijarbs.com
	Subject: Biomedical Research
Quick Response Code	
DOI: 10.22192/ijarbs.2026.13.01.013	

How to cite this article:

Venkatajothi Ramarao. (2026). Translational Biomedical Research: Bridging Infectious Diseases, Cancer Biology, Phytomedicine, and Bioinformatics. An Integrated Review. *Int. J. Adv. Res. Biol. Sci.* 13(1): 164-178.

DOI: <http://dx.doi.org/10.22192/ijarbs.2026.13.01.013>